This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Why Is Inter Parfums (IPAR) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling macroeconomic challenges, with inflation putting pressure on consumer spending and customer acquisition. Management expects revenues to decline in 2024.
Nu Skin (NUS) Q4 Earnings Top Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 results reflect the persistence of macroeconomic challenges and hurdles related to business transformation, offset by growth in some regions.
Nu Skin Enterprises (NUS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 27.59% and 1.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Things to Consider Ahead of Nu Skin's (NUS) Q4 Earnings
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations pose concerns.
Philip Morris (PM) Lags Q4 Earnings Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of -5.56% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Product Launches Aid Nu Skin (NUS), Macroeconomic Hurdles Ail
by Zacks Equity Research
Nu Skin (NUS) is benefiting from the Nu Vision 2025 strategy driven by a dynamic affiliate opportunity platform. However, escalating macroeconomic pressures are hampering key markets.
Nu Skin (NUS) Down More Than 20% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling escalating macroeconomic pressures, which are hampering key markets of the core business. Unfavorable currency translations remain a major concern.
Why Is Inter Parfums (IPAR) Up 2.8% Since Last Earnings Report?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Misses Q3 Earnings Estimates, Lowers Guidance
by Zacks Equity Research
Nu Skin (NUS) faces challenging y/y comparisons and macroeconomic hurdles in Q3, leading to a downward revision in its revenue and EPS projections for 2023.
Why Nu Skin (NUS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Nu Skin (NUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
e.l.f. Beauty (ELF) Readies for Q2 Earnings: Is a Beat Likely?
by Zacks Equity Research
e.l.f. Beauty's (ELF) strong business fundamentals, strategic acquisitions, focus on innovation and international expansion position it favorably ahead of its Q2 earnings release.
Things to Note Ahead of Nu Skin's (NUS) Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) third-quarter 2023 earnings will likely reflect macroeconomic challenges, including a slowdown in consumer spending. Nevertheless, strength in the Nu Vision 2025 strategy bodes well.
Nu Skin Enterprises (NUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nu Skin (NUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Vision 2025 Strategy Aids Nu Skin (NUS), High Costs Hurt
by Zacks Equity Research
Nu Skin (NUS) is on track with its Nu Vision 2025 strategy. However, the company is operating amid macroeconomic hurdles.
Nu Skin (NUS) Down More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is witnessing continued macroeconomic hurdles and an inflationary environment. The company is also battling unfavorable currency movements.
Nu Skin (NUS) Appears Dull on High Cost & Currency Headwinds
by Zacks Equity Research
Nu Skin's (NUS) margins have been contracting year over year for a while now. The company is also battling unfavorable currency headwinds.
Nu Skin (NUS) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling continued macroeconomic hurdles and related price increases, affecting specific key markets, leading to a slowdown in consumer spending and customer acquisition.
Nu Skin (NUS) Lowers 2023 Guidance Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin (NUS) reports sequential improvements in Q2 results, driven by the Mainland China and Rhyz segments. However, macro-economic factors pose challenges in the key markets.